ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology enterprise dedicated to developing innovative therapeutic antibodies that block CD47, a critical checkpoint signal exploited by cancer cells to evade immune system destruction. By engineering specialized fusion proteins that enhance macrophage phagocytosis, the company aims to optimize combination therapies with existing standard-of-care oncology treatments across various solid tumors and hematologic malignancies.